Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

223
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
223
Randomized Experiments01:13

Randomized Experiments

8.5K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
8.5K
Clinical Trials01:16

Clinical Trials

9.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.9K
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

54
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
54
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.1K
Blinding01:11

Blinding

3.6K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Environmental fluctuations alter the competitive trade-offs of group size in a social primate.

Nature ecology & evolution·2026
Same author

Wild parrots exhibit age-dependent conformity when learning about novel food.

PLoS biology·2026
Same author

Gabapentin Utilization and Adverse Effects Among US Hemodialysis Patients Diagnosed With Pruritus or Neuropathic Pain.

Kidney medicine·2026
Same author

Patient-Physician Language Concordance, Antihypertensive Medications, and Cardiovascular Outcomes Among Allophone-Speaking Patients with Hypertension.

CJC open·2026
Same author

Home Dialysis Transitions in Canada During the COVID-19 Pandemic: An Interrupted Time Series Analysis.

Kidney medicine·2026
Same author

Randomized Controlled Trial of Intradialytic Cycling as Kidney Exercise Rehabilitation for Cardiac Stunning in Hemodialysis (TICKERS_HD): A Clinical Research Protocol.

Canadian journal of kidney health and disease·2026

Related Experiment Video

Updated: Nov 8, 2025

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

36.9K

Randomized Controlled Trials 5: Biomarkers and Surrogates/Outcomes.

Claudio Rigatto1, Brendan J Barrett2

  • 1Department of Medicine, Seven Oaks General Hospital, University of Manitoba, Winnipeg, MB, Canada. crigatto@sbgh.mb.ca.

Methods in Molecular Biology (Clifton, N.J.)
|April 19, 2021
PubMed
Summary

Biomarkers indicate biological processes and can aid in disease diagnosis and prognosis. Validating biomarkers and surrogate outcomes in clinical studies is crucial for reliable therapeutic assessments.

Keywords:
Clinical trialsCohort studiesStatistical methods

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.8K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

17.7K

Related Experiment Videos

Last Updated: Nov 8, 2025

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

36.9K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.8K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

17.7K

Area of Science:

  • Biomedical research
  • Clinical trial methodology
  • Diagnostic and prognostic indicators

Background:

  • Biomarkers are measurable indicators of biological processes or responses to interventions.
  • They play key roles in disease diagnosis, prognosis, and as surrogates for clinical outcomes.
  • Biomarkers can reflect how patients survive, function, or feel.

Purpose of the Study:

  • To discuss the design and analysis of clinical studies for biomarker and surrogate outcome validation.
  • To highlight the importance of independent measurement of biomarkers and outcomes.
  • To emphasize the need for validation to ensure surrogate outcomes accurately reflect clinical endpoints.

Main Methods:

  • Discussion of clinical study design principles.
  • Explanation of statistical analysis considerations for biomarker validation.
  • Emphasis on independent assessment of biomarkers and clinical outcomes.

Main Results:

  • Biomarkers offer valuable insights into disease states and treatment responses.
  • Validated surrogate outcomes can provide statistically robust treatment effect estimates with smaller sample sizes.
  • Carefully designed studies are essential for establishing biomarker validity.

Conclusions:

  • Biomarker and surrogate outcome validation is critical for reliable clinical trial interpretation.
  • Independent measurement and rigorous study design ensure biomarker utility.
  • Effective validation confirms that surrogate outcomes truly represent clinical benefits.